Stem definition | Drug id | CAS RN |
---|---|---|
beta-lactamase inhibitors | 4946 | 1192500-31-4 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.24 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.76 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.93 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.70 hours | Lombardo F, Berellini G, Obach RS |
S (Water solubility) | 10 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 25, 2015 | FDA | CEREXA INC |
None
None
None
None
Source | Code | Description |
---|---|---|
FDA MoA | N0000000202 | beta Lactamase Inhibitors |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D065093 | beta-Lactamase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
FDA EPC | N0000175930 | beta Lactamase Inhibitor |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:35625 | beta-lactamase inhibitors |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pyelonephritis | indication | 45816000 | DOID:11400 |
Infectious disease of abdomen | indication | 128070006 | |
Bacterial urinary infection | indication | 312124009 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.64 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 0.5GM BASE;2GM/VIAL | AVYCAZ | ALLERGAN | N206494 | Feb. 25, 2015 | RX | POWDER | INTRAVENOUS | 7112592 | Jan. 7, 2026 | A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM |
EQ 0.5GM BASE;2GM/VIAL | AVYCAZ | ALLERGAN | N206494 | Feb. 25, 2015 | RX | POWDER | INTRAVENOUS | 7112592 | Jan. 7, 2026 | A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM |
EQ 0.5GM BASE;2GM/VIAL | AVYCAZ | ALLERGAN | N206494 | Feb. 25, 2015 | RX | POWDER | INTRAVENOUS | 7112592 | Jan. 7, 2026 | METHOD OF TREATING BACTERIAL INFECTIONS |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 0.5GM BASE;2GM/VIAL | AVYCAZ | ALLERGAN | N206494 | Feb. 25, 2015 | RX | POWDER | INTRAVENOUS | Feb. 25, 2020 | NEW CHEMICAL ENTITY |
EQ 0.5GM BASE;2GM/VIAL | AVYCAZ | ALLERGAN | N206494 | Feb. 25, 2015 | RX | POWDER | INTRAVENOUS | Feb. 25, 2025 | GENERATING ANTIBIOTIC INCENTIVES NOW |
EQ 0.5GM BASE;2GM/VIAL | AVYCAZ | ALLERGAN | N206494 | Feb. 25, 2015 | RX | POWDER | INTRAVENOUS | Dec. 20, 2025 | NEW PATIENT POPULATION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-lactamase | Enzyme | INHIBITOR | Kd | 8.16 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase | Enzyme | INHIBITOR | Kd | 6.18 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase | Enzyme | INHIBITOR | Kd | 8.70 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase TEM | Enzyme | IC50 | 8.72 | CHEMBL | |||||
Beta-lactamase | Unclassified | Ki | 5.77 | CHEMBL | |||||
Penicillin-binding protein 2 | Enzyme | IC50 | 6.23 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 7.96 | CHEMBL |
ID | Source |
---|---|
7352665165 | UNII |
D10340 | KEGG_DRUG |
4034342 | VUID |
N0000191549 | NUI |
396731-20-7 | SECONDARY_CAS_RN |
1192491-61-4 | SECONDARY_CAS_RN |
4034342 | VANDF |
C3489748 | UMLSCUI |
CHEBI:85982 | CHEBI |
FYG | PDB_CHEM_ID |
CHEMBL1689063 | ChEMBL_ID |
9835049 | PUBCHEM_CID |
DB09060 | DRUGBANK_ID |
CHEMBL2107817 | ChEMBL_ID |
8972 | INN_ID |
C543519 | MESH_SUPPLEMENTAL_RECORD_UI |
C492231 | MESH_SUPPLEMENTAL_RECORD_UI |
10761 | IUPHAR_LIGAND_ID |
1603833 | RXNORM |
30974 | MMSL |
d08357 | MMSL |
015925 | NDDF |
015926 | NDDF |
1193767002 | SNOMEDCT_US |
715180004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
AVYCAZ | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0456-2700 | POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | NDA | 30 sections |
AVYCAZ | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0456-2700 | POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | NDA | 30 sections |